From the Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany.
Department of Cardiothoracic Surgery, University Medical Center Regensburg, Regensburg, Germany.
ASAIO J. 2022 Dec 1;68(12):1529-1535. doi: 10.1097/MAT.0000000000001698. Epub 2022 Mar 16.
Bleeding and thromboembolic events are common during veno-venous extracorporeal membrane oxygenation (vvECMO). It is unknown whether these complications are driven by the ECMO system itself, multiorgan-failure, or both. The aim of this study was to assess the prevalence of bleeding and thromboembolic events in patients with isolated respiratory failure. Patients with vvECMO were retrospectively included from March 2009 to October 2017. Exclusion included any organ failure other than respiratory. Major bleeding was defined as a decrease in hemoglobin ≥2 g/dl per 24 hours, the requirement for transfusion of ≥2 packed red blood cell concentrates per 24 hours, any retroperitoneal, pulmonary, central nervous system bleeding, or bleeding requiring surgery. Thromboembolic events were assessed by duplex sonography or CT scan. Of 601 patients, 123 patients with a mean age of 49 ± 15 years and a median Sepsis-related Organ Failure Assessment score of 8 (7-9) were eligible for the analysis. Major bleeding was observed in 73%; 35% of all bleedings occurred on the day of or after ECMO initiation. A more pronounced decrease of PaCO2 after ECMO initiation was seen in patients with intracranial bleeding (ICB) compared with those without. Thromboembolic events were noted in 30%. The levels of activated prothrombin time, fibrinogen, platelet count, or D-dimers affected neither bleeding nor the prevalence of thromboembolic events.
出血和血栓栓塞事件在静脉-静脉体外膜肺氧合(vvECMO)期间很常见。目前尚不清楚这些并发症是由 ECMO 系统本身、多器官衰竭还是两者共同引起的。本研究旨在评估孤立性呼吸衰竭患者出血和血栓栓塞事件的发生率。从 2009 年 3 月至 2017 年 10 月,对接受 vvECMO 的患者进行了回顾性纳入。排除标准包括除呼吸以外的任何器官衰竭。大出血定义为血红蛋白每 24 小时下降≥2g/dl,每 24 小时需要输注≥2 个单位浓缩红细胞,任何腹膜后、肺、中枢神经系统出血,或需要手术的出血。血栓栓塞事件通过双功超声或 CT 扫描评估。在 601 例患者中,123 例年龄 49±15 岁,中位脓毒症相关器官衰竭评估评分 8(7-9),符合分析标准。73%的患者出现大出血;35%的所有出血发生在 ECMO 启动当天或之后。与无颅内出血(ICB)的患者相比,在 ECMO 启动后 PaCO2 下降更为明显的患者发生 ICB。30%的患者出现血栓栓塞事件。活化的凝血酶原时间、纤维蛋白原、血小板计数或 D-二聚体水平既不影响出血,也不影响血栓栓塞事件的发生率。